NDA 202236 · Mylan Speciality Lp
Dymista
Azelastine Hydrochloride, Fluticasone Propionate · Nasal
Last checked: Nov 20, 2026Latest source record: Dec 17, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
May 1, 2012
Approved uses
2
Original approval plus efficacy supplements
Registered trials
62
23 Phase 3, 1 recruiting
FAERS reports
4,131
2,443 serious, 65 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 15, 2024.
Azelastine hydrochloride and fluticasone propionate nasal spray is indicated for the relief of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older. Azelastine hydrochloride and fluticasone propionate nasal spray contains an H 1 -receptor antagonist and a corticosteroid, and is indicated for the relief of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older. ( 1 )
Mechanism: Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray Azelastine hydrochloride and fluticasone propionate nasal spray contains both azelastine hydrochloride and fluticasone propionate; therefore, the mechanisms of actions described below for the individual components apply to azelastine hydrochloride and fluticasone propionate nasal spray. These drugs represent two different classes of medications (histamine H 1 -receptor antagonist and synthetic corticosteroid). Azelastine Hydrochloride Azelastine hydrochloride, a phthalazinone derivative, exhibits histamine H 1 -receptor...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 20, 2015 Supplement 8 · Efficacy · priority review LabelPediatric Written RequestPediatric Medical Review
- May 1, 2012 Original approval · Type 4 - New Combination LabelReviewSummary Review
1 products under this application
- DYMISTA · AZELASTINE HYDROCHLORIDE 0.137MG/SPRAY; FLUTICASONE PROPIONATE 0.05MG/SPRAY · SPRAY, METERED, NASAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Azelastine" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal AllergiesPivotal-lookingCompleted
Meda PharmaceuticalsIndustry
NCT00883168 · 1,791 participants · Start Apr 2009 · Primary completion Jul 2009
Drug: Placebo; azelastineHcl and 2 more · For: Seasonal Allergic Rhinitis
Sites: Scottsdale, Arizona; Encinitas, California; Fountain Valley, California · 45 sites in all
- Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™Pivotal-lookingStatus unknown
Teva Pharmaceuticals USATeva (TEVA)
NCT02249663 · 1,535 participants (planned) · Start Aug 2014 · Primary completion Feb 2015
Drug: Azelastine hydrochloride and Fluticasone propionate; Dymista™ · For: Seasonal Allergic Rhinitis
Sites: Pittsburgh, Pennsylvania
- Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic RhinitisPivotal-lookingCompleted
Padagis LLCIndustry
NCT02230696 · 951 participants · Start Aug 2014 · Primary completion Feb 2015
Drug: Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray; Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray and 1 more · For: Seasonal Allergic Rhinitis
Sites: Stockbridge, Georgia; Louisville, Kentucky; Baltimore, Maryland · 30 sites in all
- DYmista NAsal Spray in CHInese PatientsPivotal-lookingCompleted
MEDA Pharma GmbH & Co. KGIndustry
NCT03599791 · 900 participants · Start Jun 29, 2018 · Primary completion Sep 24, 2019
Drug: Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT; Azelastine Hydrochloride 0.137 MG/ACTUAT and 1 more · For: Allergic Rhinitis
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 33 sites in all
- Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic RhinitisPivotal-lookingCompleted
Meda PharmaceuticalsIndustry
NCT00783432 · 862 participants · Start Jul 2006 · Primary completion Dec 2007
Drug: Astepro Nasal Spray (0.1% azelastine hydrochloride); Astelin Nasal Spray (0.1% azelastine hydrochloride) · For: Chronic Allergic Rhinitis; Nonallergic Rhinitis
Sites: Somerset, New Jersey
- A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal AllergiesPivotal-lookingCompleted
Meda PharmaceuticalsIndustry
NCT00651118 · 832 participants · Start Mar 2008 · Primary completion Jun 2008
Drug: Placebo; azelastine Hcl and 2 more · For: Seasonal Allergic Rhinitis
Sites: Scottsdale, Arizona; Encinitas, California; Los Angeles, California · 43 sites in all
- A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal AllergiesPivotal-lookingCompleted
Meda PharmaceuticalsIndustry
NCT00740792 · 776 participants · Start Aug 2008 · Primary completion Nov 2008
Drug: azelastine HCl/fluticasone propionate; azelastine Hcl and 2 more · For: Seasonal Allergic Rhinitis
Sites: Scottsdale, Arizona; Encinitas, California; Fountain Valley, California · 39 sites in all
- A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic RhinitisPivotal-lookingCompleted
Meda PharmaceuticalsIndustry
NCT00720382 · 703 participants · Start Mar 2007 · Primary completion Jun 2008
Drug: 0.15% azelastine hydrochloride; Mometasone furoate · For: Perennial Allergic Rhinitis
Sites: Oxford, Alabama; Fountain Valley, California; Huntington Beach, California · 59 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea328
- drug ineffective311
- fatigue287
- headache278
- asthma267
- cough256
- nausea241
- sinusitis204
- pneumonia202
- dizziness180
- off label use176
- diarrhoea158
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2012 | 5 |
| 2013 | 19 |
| 2014 | 72 |
| 2015 | 556 |
| 2016 | 444 |
| 2017 | 334 |
| 2018 | 366 |
| 2019 | 395 |
| 2020 | 390 |
| 2021 | 272 |
| 2022 | 257 |
| 2023 | 254 |
| 2024 | 321 |
| 2025 | 266 |
| 2026 | 179 |
Recalls
2 FDA enforcement reports for this application.
Feb 1, 2019 · Class II · Terminated
Defective Container: Potential for broken glass in the neck area of the glass bottles.
Jul 25, 2018 · Class II · Terminated
Presence of foreign substance: Potential for glass in the neck area of the glass bottles.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Dymista (Azelastine/Fluticasone)
2024 spending
$604K
Beneficiaries
816
2,117 claims
Per beneficiary
$741
$8.63 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,622,713 |
| 2021 | $2,743,947 |
| 2022 | $1,901,225 |
| 2023 | $486,687 |
| 2024 | $604,311 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Intranasal antihistamines and corticosteroids in allergic rhinitis: A systematic review and meta-analysis.
Sousa-Pinto B, Vieira RJ, Brozek J, et al. · J Allergy Clin Immunol 2024 · Systematic Review, Meta-Analysis
- Efficacy and safety of intranasal medications for allergic rhinitis: Network meta-analysis.
Sousa-Pinto B, Vieira RJ, Bognanni A, et al. · Allergy 2025 · Systematic Review, Network Meta-Analysis
- Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients.
Klussmann JP, Grosheva M, Meiser P, et al. · Sci Rep 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial.
Lehr T, Meiser P, Selzer D, et al. · JAMA Intern Med 2025 · Clinical Trial, Phase II, Randomized Controlled Trial
- Intranasal spray medications for maintenance therapy of allergic rhinitis.
Berger WE, Meltzer EO · Am J Rhinol Allergy 2015 · Research Support, Non-U.S. Gov't, Systematic Review
- Second-generation antihistamines: a comparative review.
Slater JW, Zechnich AD, Haxby DG · Drugs 1999 · Meta-Analysis
Sponsor: Mylan Speciality Lp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.